Samaritan Pharmaceuticals Inc. Gets Notification That European Patent Has Been Granted To Its SP-1000 Drug For Treatment Of Cardiovascular Disease
Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today it has received a notice that a European Patent has been granted to Samaritanís SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease.
The European patent is an examined document, and is enforceable as a patent after registration requirements have been fulfilled in designated countries. Samaritan is taking the appropriate steps to register the patent in the following European countries: Austria, Belgium, Switzerland/Liechtenstein, Spain, France, Great Britain, Italy, the Netherlands, and Sweden.
Previously on May 22, 2006, Samaritan announced that its collaborating scientists in two preclinical animal studies found that SP-1000 reduces blood cholesterol, clears plaque from clogged arteries, and raises HDL -- the good cholesterol.
The patent has been awarded to Georgetown University and is exclusively licensed to Samaritan. The patent duration is 20 years from the filing date (i.e., March 12, 2019).
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.